CD274 and hepatocellular carcinoma: We also applied 3.0 as cut-off value for PD-L1 in the 154 unselected HCC patients, and the difference in RFS remained insignificant (p = 0.254) between the two groups (Figure S2), with a median RFS of 27.6 (95%CI: 19.7–35.5) months in patients with lower expression of PD-L1 (N = 100) and 15.0 (95%CI: 7.5–22.5) months in the PD-L1 overexpressed group (N = 54).